Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN68,368,480,20
Msft-0,25
Nokia3,5143,5482,13
IBM0,25
Mercedes-Benz Group AG68,4268,430,25
PFE1,54
14.05.2024 8:30:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.05.2024 18:00:00
Biotage (BIOT.ST, Stockholm)
Závěr k 13.5.2024 Změna (%) Změna (SEK) Objem obchodů (SEK)
169,80 -0,12 -0,20 7 031 357
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.05.2024
Popis společnosti
Obecné informace
Název společnostiBiotage AB
TickerBIOT
Kmenové akcie:Ordinary Shares
RICBIOT.ST
ISINSE0000454746
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.03.2024
Počet zaměstnanců k 31.03.2024 669
Akcie v oběhu k 31.03.2024 80 008 185
MěnaSEK
Kontaktní informace
UliceVimpelgatan 5
MěstoUPPSALA
PSČ753 18
ZeměSweden
Kontatní osoba 
Funkce kontaktní osoby 
Telefon4 618 565 900
Fax4618591922

Business Summary: Biotage AB is a Sweden-based company that develops and sells systems, consumables and services in the field of life sciences. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The Company offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Biotage AB revenues increased 33% to SEK480M. Net income decreased 23% to SEK33M. Revenues reflect EMEA segment increase from SEK96M to SEK210M, Americas segment increase of 16% to SEK189M. Net income was offset by Distribution costs increase of 43% to SEK136M (expense), Net financial items decrease from SEK2M (income) to SEK25M (expense).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Medical Diagnostic & Testing Equipment
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSAnalytical Laboratory Instrument Manufacturing
NAICS2007Electromedical Apparatus Mfg
NAICS2007Analytical Laboratory Instrument Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Analytical Laboratory Instrument Manufacturing
SICElectromedical Equipment
SICAnalytical Instruments



  • Poslední aktualizace: 14.05.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Interim President and Chief Executive Officer, DirectorTorben Joergensen7204.01.202427.04.2006
Chief Financial OfficerAndrew Kellett5615.02.202411.09.2023
President, AmericasScott Carr57
President InternationalAndreas Juhlin50
Chief Human Resource Officer and Sustainability OfficerPetra Duprez59
Executive Vice President - Global MarketingRaffaella Bombarda50
Executive Vice President - Quality Assurance Regulatory AffairsLisa Egelrud49
Executive Vice President - Business DevelopmentOlof Nord49
Executive Vice President - IT and DigitalizationMagnus Nordstedt54
Executive Vice President - OperationsAnders Wikstroem51